Novo Nordisk A/S (CPH:NOVO.B)
237.90
-3.60 (-1.49%)
Mar 19, 2026, 4:59 PM CET
Novo Nordisk Revenue
In the year 2025, Novo Nordisk had annual revenue of 309.06B DKK with 6.43% growth. Novo Nordisk had revenue of 79.14B in the quarter ending December 31, 2025, a decrease of -7.63%.
Revenue
309.06B
Revenue Growth
+6.43%
P/S Ratio
3.47
Revenue / Employee
4.47M
Employees
69,505
Market Cap
1.07T
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 309.06B | 18.66B | 6.43% |
| Dec 31, 2024 | 290.40B | 58.14B | 25.03% |
| Dec 31, 2023 | 232.26B | 55.31B | 31.26% |
| Dec 31, 2022 | 176.95B | 36.15B | 25.68% |
| Dec 31, 2021 | 140.80B | 13.85B | 10.91% |
| Dec 31, 2020 | 126.95B | 4.93B | 4.04% |
| Dec 31, 2019 | 122.02B | 10.19B | 9.11% |
| Dec 31, 2018 | 111.83B | 135.00M | 0.12% |
| Dec 31, 2017 | 111.70B | -84.00M | -0.08% |
| Dec 31, 2016 | 111.78B | 3.85B | 3.57% |
| Dec 31, 2015 | 107.93B | 19.12B | 21.53% |
| Dec 31, 2014 | 88.81B | 5.23B | 6.26% |
| Dec 31, 2013 | 83.57B | 5.55B | 7.11% |
| Dec 31, 2012 | 78.03B | 11.68B | 17.60% |
| Dec 31, 2011 | 66.35B | 5.57B | 9.16% |
| Dec 31, 2010 | 60.78B | 9.70B | 18.99% |
| Dec 31, 2009 | 51.08B | 5.53B | 12.13% |
| Dec 31, 2008 | 45.55B | 3.72B | 8.90% |
| Dec 31, 2007 | 41.83B | 3.09B | 7.97% |
| Dec 31, 2006 | 38.74B | 4.98B | 14.76% |
| Dec 31, 2005 | 33.76B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Coloplast | 27.89B |
| H. Lundbeck | 24.63B |
| Genmab | 23.66B |
| Demant | 22.97B |
| GN Store Nord | 16.78B |
| Zealand Pharma | 9.21B |
| ALK-Abelló | 6.31B |
| Bavarian Nordic | 6.24B |
Novo Nordisk News
- 1 hour ago - A high dose of Wegovy helped people lose 21% of their weight. It was just approved. - Market Watch
- 2 hours ago - Novo Nordisk Secures FDA Approval For Higher-Dose Wegovy - Benzinga
- 3 hours ago - Novo Nordisk's Higher Dose Wegovy Weight-Loss Drug Gains U.S. Approval - WSJ
- 3 hours ago - FDA approves higher dose version of weight loss drug Wegovy as Novo Nordisk tries to win back market share - CNBC
- 4 hours ago - FDA approves Novo Nordisk's new Wegovy® HD injection, delivering the highest weight loss to date for a Wegovy® injection, adding to its already expansive clinical profile - PRNewsWire
- 4 hours ago - US FDA approves higher dose of Wegovy - Reuters
- 4 hours ago - Novo Nordisk A/S: Wegovy® HD (semaglutide 7.2 mg) approved in the US, providing 20.7% mean weight loss - GlobeNewsWire
- 7 hours ago - A ₹1500 weight loss drug? The opportunity and the danger for India - Business Upturn